These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 15327513

  • 1. DNA hypo-methylating agents and sickle cell disease.
    Saunthararajah Y, Lavelle D, DeSimone J.
    Br J Haematol; 2004 Sep; 126(5):629-36. PubMed ID: 15327513
    [Abstract] [Full Text] [Related]

  • 2. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
    Saunthararajah Y, DeSimone J.
    Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
    [Abstract] [Full Text] [Related]

  • 3. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
    Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J.
    Blood; 2003 Dec 01; 102(12):3865-70. PubMed ID: 12907443
    [Abstract] [Full Text] [Related]

  • 4. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.
    Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, Will R, Hankewych M, Roxas B, Singh M, Saunthararajah Y, Desimone J.
    Am J Hematol; 2007 Nov 01; 82(11):981-5. PubMed ID: 17696208
    [Abstract] [Full Text] [Related]

  • 5. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
    DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N.
    Blood; 2002 Jun 01; 99(11):3905-8. PubMed ID: 12010787
    [Abstract] [Full Text] [Related]

  • 6. Therapies to increase fetal hemoglobin in sickle cell disease.
    Steinberg MH.
    Curr Hematol Rep; 2003 Mar 01; 2(2):95-101. PubMed ID: 12901139
    [Abstract] [Full Text] [Related]

  • 7. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
    Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J.
    Blood; 2000 Oct 01; 96(7):2379-84. PubMed ID: 11001887
    [Abstract] [Full Text] [Related]

  • 8. Induction of fetal hemoglobin in the treatment of sickle cell disease.
    Fathallah H, Atweh GF.
    Hematology Am Soc Hematol Educ Program; 2006 Oct 01; ():58-62. PubMed ID: 17124041
    [Abstract] [Full Text] [Related]

  • 9. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
    Fathallah H.
    Clin Adv Hematol Oncol; 2008 Nov 01; 6(11):806-8. PubMed ID: 19194363
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacologic manipulation of fetal hemoglobin synthesis.
    Dover GJ, Humphries RK, Young N, Ley T, Boyer S, Charache S, Nienhuis A.
    Prog Clin Biol Res; 1985 Nov 01; 191():447-54. PubMed ID: 2413480
    [Abstract] [Full Text] [Related]

  • 11. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
    Christman JK.
    Oncogene; 2002 Aug 12; 21(35):5483-95. PubMed ID: 12154409
    [Abstract] [Full Text] [Related]

  • 12. Clinical effectiveness of decitabine in severe sickle cell disease.
    Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.
    Br J Haematol; 2008 Apr 12; 141(1):126-9. PubMed ID: 18324975
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
    Atweh GF, Schechter AN.
    Curr Opin Hematol; 2001 Mar 12; 8(2):123-30. PubMed ID: 11224687
    [Abstract] [Full Text] [Related]

  • 14. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.
    PLoS Med; 2017 Sep 12; 14(9):e1002382. PubMed ID: 28880867
    [Abstract] [Full Text] [Related]

  • 15. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.
    Dover GJ, Charache SH, Boyer SH, Talbot CC, Smith KD.
    Prog Clin Biol Res; 1983 Sep 12; 134():475-88. PubMed ID: 6198661
    [Abstract] [Full Text] [Related]

  • 16. Haemoglobin F modulation in childhood sickle cell disease.
    Trompeter S, Roberts I.
    Br J Haematol; 2009 Feb 12; 144(3):308-16. PubMed ID: 19036119
    [Abstract] [Full Text] [Related]

  • 17. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B, Robbel C, Wijermans P, Lübbert M.
    Ann Hematol; 2005 Dec 12; 84 Suppl 1():32-8. PubMed ID: 16292549
    [Abstract] [Full Text] [Related]

  • 18. DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications.
    Fathallah H, Atweh GF.
    Blood Rev; 2006 Jul 12; 20(4):227-34. PubMed ID: 16513230
    [Abstract] [Full Text] [Related]

  • 19. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.
    Charache S, Dover G, Smith K, Talbot CC, Moyer M, Boyer S.
    Proc Natl Acad Sci U S A; 1983 Aug 12; 80(15):4842-6. PubMed ID: 6192443
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic induction of fetal hemoglobin production.
    Atweh G, Fathallah H.
    Hematol Oncol Clin North Am; 2010 Dec 12; 24(6):1131-44. PubMed ID: 21075284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.